United States · Exchanges & live quotes · Nasdaq

Bristol Myers Squibb vs. Eli Lilly: How Long Can Zepbound and Mounjaro Keep Juicing Revenue Results?

Published by Nasdaq · United States 2 h ago

Key PointsWhen evaluating the two companies based strictly on the most recent quarterly data, Eli Lilly currently shows a higher overall revenue base and a demonstrably faster…

Read the full article on Nasdaq Sign in to save

MarketNews shows the headline and summary published by the outlet. The full article is on the publisher's website. (www.nasdaq.com)

Also worth reading

OilPrice.com

Grid Constraints Curtailed 119 GW of Renewables in India in September

Investopedia

Stock Market Today: Tech Stocks Lead Futures Sharply Lower; Oil Prices Surge on Middle East Escalations

CoinMarketCap

Cosmos (ATOM) Falls 2.94% Amid Broad Crypto Market Pullback

Cboe Global Markets

State of the Options Industry Q3 2026: Volume Growth Concentrated in Index and ETF Options

Google Finance